{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T14:21:10Z","timestamp":1781101270080,"version":"3.54.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T00:00:00Z","timestamp":1696377600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T00:00:00Z","timestamp":1696377600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100010256","name":"Guangzhou Municipal Science and Technology Project","doi-asserted-by":"publisher","award":["202201010981"],"award-info":[{"award-number":["202201010981"]}],"id":[{"id":"10.13039\/501100010256","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82200221"],"award-info":[{"award-number":["82200221"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82070220"],"award-info":[{"award-number":["82070220"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"5010 Clinical Research Project of Sun Yat-sen University","award":["2017005"],"award-info":[{"award-number":["2017005"]}]},{"DOI":"10.13039\/501100003453","name":"Guangdong Natural Science Foundation","doi-asserted-by":"crossref","award":["2021A1515011715"],"award-info":[{"award-number":["2021A1515011715"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Thrombosis J"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Individuals with multiple myeloma (MM) receiving immunomodulatory drugs (IMiDs) are at risk of developing venous thromboembolism (VTE), a serious complication. There is no established clinical model for predicting VTE in the Chinese population. We develop a new risk assessment model (RAM) for IMiD-associated VTE in Chinese MM patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively selected 1334 consecutive MM patients receiving IMiDs from 16 medical centers in China and classified them randomly into the derivation and validation cohorts. A multivariate Cox regression model was used for analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The overall incidence of IMiD-related VTE in Chinese MM patients was 6.1%. Independent predictive factors of VTE (diabetes, ECOG performance status, erythropoietin-stimulating agent use, dexamethasone use, and VTE history or family history of thrombosis) were identified and merged to develop the RAM. The model identified approximately 30% of the patients in each cohort at high risk for VTE. The hazard ratios (HRs) were 6.08 (P\u2009&lt;\u20090.001) and 6.23 (P\u2009&lt;\u20090.001) for the high-risk subcohort and the low-risk subcohort, respectively, within both the derivation and validation cohorts. The RAM achieved satisfactory discrimination with a C statistic of 0.64. The stratification approach of the IMWG guidelines yielded respective HRs of 1.77 (P\u2009=\u20090.053) and 1.81 (P\u2009=\u20090.063). The stratification approach of the SAVED score resulted in HRs of 3.23 (P\u2009=\u20090.248) and 1.65 (P\u2009=\u20090.622), respectively. The IMWG guideline and the SAVED score-based method yielded C statistics of 0.58 and 0.51, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The new RAM outperformed the IMWG guidelines and the SAVED score and could potentially guide the VTE prophylaxis strategy for Chinese MM patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12959-023-00534-y","type":"journal-article","created":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T13:02:10Z","timestamp":1696424530000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Development and validation of a new risk assessment model for immunomodulatory drug-associated venous thrombosis among Chinese patients with multiple myeloma"],"prefix":"10.1186","volume":"21","author":[{"given":"Xiaozhe","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuli","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baijun","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Leng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangfang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaomei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihong","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qimei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kejie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinhai","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Geng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqiang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongming","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaotao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongmei","family":"Jing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueyi","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenming","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,4]]},"reference":[{"issue":"3","key":"534_CR1","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1111\/j.1538-7836.2007.02374.x","volume":"5","author":"AA Khorana","year":"2007","unstructured":"Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost. 2007;5(3):632\u20134.","journal-title":"J Thromb Haemost"},{"key":"534_CR2","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1186\/s12957-015-0592-8","volume":"13","author":"J Khalil","year":"2015","unstructured":"Khalil J, Bensaid B, Elkacemi H, Afif M, Bensaid Y, Kebdani T, et al. Venous thromboembolism in cancer patients: an underestimated major health problem. World J Surg Oncol. 2015;13:204.","journal-title":"World J Surg Oncol"},{"key":"534_CR3","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1182\/asheducation-2010.1.437","volume":"2010","author":"SY Kristinsson","year":"2010","unstructured":"Kristinsson SY. Thrombosis in multiple myeloma. Hematol Am Soc Hematol Educ Program. 2010;2010:437\u201344.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"10","key":"534_CR4","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.3324\/haematol.2012.064444","volume":"97","author":"SY Kristinsson","year":"2012","unstructured":"Kristinsson SY, Pfeiffer RM, Bjorkholm M, Schulman S, Landgren O. Thrombosis is associated with inferior survival in multiple myeloma. Haematologica. 2012;97(10):1603\u20137.","journal-title":"Haematologica"},{"issue":"4","key":"534_CR5","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1111\/j.1538-7836.2011.04215.x","volume":"9","author":"M Carrier","year":"2011","unstructured":"Carrier M, Le Gal G, Tay J, Wu C, Lee AY. Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysis. J Thromb Haemost. 2011;9(4):653\u201363.","journal-title":"J Thromb Haemost"},{"key":"534_CR6","doi-asserted-by":"crossref","unstructured":"Fotiou D, Gavriatopoulou M, Terpos E. Multiple myeloma and thrombosis: Prophylaxis and Risk Prediction Tools. Cancers (Basel). 2020;12(1).","DOI":"10.3390\/cancers12010191"},{"issue":"1","key":"534_CR7","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/cam4.1927","volume":"8","author":"HA Baker","year":"2019","unstructured":"Baker HA, Brown AR, Mahnken JD, Shireman TI, Webb CE, Lipe BC. Application of risk factors for venous thromboembolism in patients with multiple myeloma starting chemotherapy, a real-world evaluation. Cancer Med. 2019;8(1):455\u201362.","journal-title":"Cancer Med"},{"issue":"5","key":"534_CR8","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1097\/MBC.0b013e32832b27e6","volume":"20","author":"GP Talamo","year":"2009","unstructured":"Talamo GP, Ibrahim S, Claxton D, Tricot GJ, Fink LM, Zangari M. Hypercoagulable states in patients with multiple myeloma can affect the thalidomide-associated venous thromboembolism. Blood Coagul Fibrinolysis. 2009;20(5):337\u20139.","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"5","key":"534_CR9","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1002\/pds.4180","volume":"26","author":"A Palmaro","year":"2017","unstructured":"Palmaro A, Rouge-Bugat ME, Gauthier M, Despas F, Moulis G, Lapeyre-Mestre M. Real-life practices for preventing venous thromboembolism in multiple myeloma patients: a cohort study from the french health insurance database. Pharmacoepidemiol Drug Saf. 2017;26(5):578\u201386.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"3","key":"534_CR10","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1586\/era.11.214","volume":"12","author":"SY Kristinsson","year":"2012","unstructured":"Kristinsson SY, Landgren O. Thromboprophylaxis in multiple myeloma: is the evidence there? Expert Rev Anticancer Ther. 2012;12(3):291\u20134.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"9","key":"534_CR11","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1002\/ajh.23504","volume":"88","author":"T Bagratuni","year":"2013","unstructured":"Bagratuni T, Kastritis E, Politou M, Roussou M, Kostouros E, Gavriatopoulou M, et al. Clinical and genetic factors associated with venous thromboembolism in myeloma patients treated with lenalidomide-based regimens. Am J Hematol. 2013;88(9):765\u201370.","journal-title":"Am J Hematol"},{"issue":"7","key":"534_CR12","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1001\/jamaoncol.2016.3350","volume":"3","author":"W Li","year":"2017","unstructured":"Li W, Garcia D, Cornell RF, Gailani D, Laubach J, Maglio ME, et al. Cardiovascular and thrombotic complications of Novel multiple myeloma therapies: a review. JAMA Oncol. 2017;3(7):980\u20138.","journal-title":"JAMA Oncol"},{"issue":"2","key":"534_CR13","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1038\/sj.leu.2405062","volume":"22","author":"A Palumbo","year":"2008","unstructured":"Palumbo A, Rajkumar SV, Dimopoulos MA, Richardson PG, San Miguel J, Barlogie B, et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia. 2008;22(2):414\u201323.","journal-title":"Leukemia"},{"issue":"6","key":"534_CR14","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1200\/JCO.2013.48.7934","volume":"32","author":"A Palumbo","year":"2014","unstructured":"Palumbo A, Rajkumar SV, San Miguel JF, Larocca A, Niesvizky R, Morgan G, et al. International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. J Clin Oncol. 2014;32(6):587\u2013600.","journal-title":"J Clin Oncol"},{"issue":"7","key":"534_CR15","doi-asserted-by":"publisher","first-page":"840","DOI":"10.6004\/jnccn.2018.7273","volume":"17","author":"A Li","year":"2019","unstructured":"Li A, Wu Q, Luo S, Warnick GS, Zakai NA, Libby EN, et al. Derivation and validation of a risk Assessment Model for Immunomodulatory Drug-Associated thrombosis among patients with multiple myeloma. J Natl Compr Canc Netw. 2019;17(7):840\u20137.","journal-title":"J Natl Compr Canc Netw"},{"issue":"9","key":"534_CR16","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1182\/blood.2020005125","volume":"136","author":"CA Bradbury","year":"2020","unstructured":"Bradbury CA, Craig Z, Cook G, Pawlyn C, Cairns DA, Hockaday A, et al. Thrombosis in patients with myeloma treated in the myeloma IX and myeloma XI phase 3 randomized controlled trials. Blood. 2020;136(9):1091\u2013104.","journal-title":"Blood"},{"issue":"4","key":"534_CR17","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1001\/archinte.166.4.458","volume":"166","author":"HK Chew","year":"2006","unstructured":"Chew HK, Wun T, Harvey D, Zhou H, White RH. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med. 2006;166(4):458\u201364.","journal-title":"Arch Intern Med"},{"issue":"2","key":"534_CR18","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.thromres.2012.11.014","volume":"131","author":"A Kato","year":"2013","unstructured":"Kato A, Takano H, Ichikawa A, Koshino M, Igarashi A, Hattori K, et al. A retrospective cohort study of venous thromboembolism(VTE) in 1035 japanese myeloma patients treated with thalidomide; lower incidence without statistically significant association between specific risk factors and development of VTE and effects of thromboprophylaxis with aspirin and warfarin. Thromb Res. 2013;131(2):140\u20134.","journal-title":"Thromb Res"},{"key":"534_CR19","unstructured":"Shyu BH, Po-Nan W, Pao-Hsien CJA-PJoO. Hematology. Low incidence of venous thromboembolism in asian myeloma patients treated with Thalidomide plus Dexamethasone. 2010;2(1):41\u20137."},{"issue":"2","key":"534_CR20","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s00277-009-0807-6","volume":"89","author":"Y Koh","year":"2010","unstructured":"Koh Y, Bang SM, Lee JH, Yoon HJ, Do YR, Ryoo HM, et al. Low incidence of clinically apparent thromboembolism in korean patients with multiple myeloma treated with thalidomide. Ann Hematol. 2010;89(2):201\u20136.","journal-title":"Ann Hematol"},{"issue":"11","key":"534_CR21","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1002\/ajh.25603","volume":"94","author":"KM Sanfilippo","year":"2019","unstructured":"Sanfilippo KM, Luo S, Wang TF, Fiala M, Schoen M, Wildes TM, et al. Predicting venous thromboembolism in multiple myeloma: development and validation of the IMPEDE VTE score. Am J Hematol. 2019;94(11):1176\u201384.","journal-title":"Am J Hematol"},{"issue":"1","key":"534_CR22","doi-asserted-by":"publisher","first-page":"8","DOI":"10.6004\/jnccn.2022.0002","volume":"20","author":"NS Callander","year":"2022","unstructured":"Callander NS, Baljevic M, Adekola K, Anderson LD, Campagnaro E, Castillo JJ, et al. NCCN Guidelines(R) insights: multiple myeloma, Version 3.2022. J Natl Compr Canc Netw. 2022;20(1):8\u201319.","journal-title":"J Natl Compr Canc Netw"},{"issue":"10","key":"534_CR23","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.3324\/haematol.2014.117176","volume":"100","author":"E Terpos","year":"2015","unstructured":"Terpos E, Kleber M, Engelhardt M, Zweegman S, Gay F, Kastritis E, et al. European Myeloma Network guidelines for the management of multiple myeloma-related complications. Haematologica. 2015;100(10):1254\u201366.","journal-title":"Haematologica"},{"issue":"1","key":"534_CR24","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S1470-2045(09)70284-0","volume":"11","author":"SV Rajkumar","year":"2010","unstructured":"Rajkumar SV, Jacobus S, Callander NS, Fonseca R, Vesole DH, Williams ME, et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol. 2010;11(1):29\u201337.","journal-title":"Lancet Oncol"},{"issue":"3","key":"534_CR25","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1200\/JCO.2005.03.0221","volume":"24","author":"SV Rajkumar","year":"2006","unstructured":"Rajkumar SV, Blood E, Vesole D, Fonseca R, Greipp PR, Eastern Cooperative Oncology G. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol. 2006;24(3):431\u20136.","journal-title":"J Clin Oncol"},{"key":"534_CR26","doi-asserted-by":"crossref","unstructured":"Schoen MW, Luo S, Gage B, Carson KR, Sanfilippo KMJJoCO. Association of venous thromboembolism with increased mortality in patients with multiple myeloma. 2018;36(15_suppl):8051-.","DOI":"10.1200\/JCO.2018.36.15_suppl.8051"},{"issue":"5","key":"534_CR27","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1182\/blood.V98.5.1614","volume":"98","author":"M Zangari","year":"2001","unstructured":"Zangari M, Anaissie E, Barlogie B, Badros A, Desikan R, Gopal AV, et al. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood. 2001;98(5):1614\u20135.","journal-title":"Blood"},{"issue":"2","key":"534_CR28","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1002\/(SICI)1096-8652(200002)63:2<74::AID-AJH3>3.0.CO;2-V","volume":"63","author":"CH Ho","year":"2000","unstructured":"Ho CH, Chau WK, Hsu HC, Gau JP, Yu TJ. Causes of venous thrombosis in fifty chinese patients. Am J Hematol. 2000;63(2):74\u20138.","journal-title":"Am J Hematol"},{"issue":"5","key":"534_CR29","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/S0049-3848(00)00265-6","volume":"99","author":"MC Shen","year":"2000","unstructured":"Shen MC, Lin JS, Tsay W. Protein C and protein S deficiencies are the most important risk factors associated with thrombosis in chinese venous thrombophilic patients in Taiwan. Thromb Res. 2000;99(5):447\u201352.","journal-title":"Thromb Res"},{"issue":"29","key":"534_CR30","doi-asserted-by":"publisher","first-page":"4865","DOI":"10.1200\/JCO.2009.22.3875","volume":"27","author":"M Zangari","year":"2009","unstructured":"Zangari M, Fink LM, Elice F, Zhan F, Adcock DM, Tricot GJ. Thrombotic events in patients with cancer receiving antiangiogenesis agents. J Clin Oncol. 2009;27(29):4865\u201373.","journal-title":"J Clin Oncol"},{"issue":"21","key":"534_CR31","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1056\/NEJMoa070594","volume":"357","author":"M Dimopoulos","year":"2007","unstructured":"Dimopoulos M, Spencer A, Attal M, Prince HM, Harousseau JL, Dmoszynska A, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med. 2007;357(21):2123\u201332.","journal-title":"N Engl J Med"},{"issue":"5","key":"534_CR32","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1080\/17474086.2020.1751608","volume":"13","author":"TS Chan","year":"2020","unstructured":"Chan TS, Hwang YY, Tse E. Risk assessment of venous thromboembolism in hematological cancer patients: a review. Expert Rev Hematol. 2020;13(5):471\u201380.","journal-title":"Expert Rev Hematol"},{"issue":"3","key":"534_CR33","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.thromres.2015.07.004","volume":"136","author":"B Zoller","year":"2015","unstructured":"Zoller B, Palmer K, Li X, Sundquist J, Sundquist K. Family history of venous thromboembolism and risk of hospitalized thromboembolism in cancer patients: a nationwide family study. Thromb Res. 2015;136(3):573\u201381.","journal-title":"Thromb Res"},{"issue":"7","key":"534_CR34","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1080\/17474086.2016.1194750","volume":"9","author":"D Fotiou","year":"2016","unstructured":"Fotiou D, Gerotziafas G, Kastritis E, Dimopoulos MA, Terpos E. A review of the venous thrombotic issues associated with multiple myeloma. Expert Rev Hematol. 2016;9(7):695\u2013706.","journal-title":"Expert Rev Hematol"},{"issue":"3","key":"534_CR35","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1055\/s-0034-1370793","volume":"40","author":"V De Stefano","year":"2014","unstructured":"De Stefano V, Za T, Rossi E. Venous thromboembolism in multiple myeloma. Semin Thromb Hemost. 2014;40(3):338\u201347.","journal-title":"Semin Thromb Hemost"},{"issue":"1","key":"534_CR36","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s11239-015-1311-6","volume":"41","author":"JA Heit","year":"2016","unstructured":"Heit JA, Spencer FA, White RH. The epidemiology of venous thromboembolism. J Thromb Thrombolysis. 2016;41(1):3\u201314.","journal-title":"J Thromb Thrombolysis"},{"issue":"Suppl 4","key":"534_CR37","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/S0049-3848(09)70136-7","volume":"123","author":"RH White","year":"2009","unstructured":"White RH, Keenan CR. Effects of race and ethnicity on the incidence of venous thromboembolism. Thromb Res. 2009;123(Suppl 4):11\u20137.","journal-title":"Thromb Res"},{"issue":"6","key":"534_CR38","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1111\/j.1365-2141.2005.05529.x","volume":"129","author":"A Cortelezzi","year":"2005","unstructured":"Cortelezzi A, Moia M, Falanga A, Pogliani EM, Agnelli G, Bonizzoni E, et al. Incidence of thrombotic complications in patients with haematological malignancies with central venous catheters: a prospective multicentre study. Br J Haematol. 2005;129(6):811\u20137.","journal-title":"Br J Haematol"}],"container-title":["Thrombosis Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12959-023-00534-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12959-023-00534-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12959-023-00534-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T09:17:57Z","timestamp":1700212677000},"score":1,"resource":{"primary":{"URL":"https:\/\/thrombosisjournal.biomedcentral.com\/articles\/10.1186\/s12959-023-00534-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,4]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["534"],"URL":"https:\/\/doi.org\/10.1186\/s12959-023-00534-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2168582\/v1","asserted-by":"object"}]},"ISSN":["1477-9560"],"issn-type":[{"value":"1477-9560","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,4]]},"assertion":[{"value":"15 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Each hospital\u2019s institutional review board examined and approved the research protocol before it could be implemented. The recommendations of the Declaration of Helsinki for biomedical research involving human subjects were adhered to in a strict manner.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"105"}}